FGFR4 and breast carcinoma: Moreover, FGFR4 amplification or overexpression, which are associated with a poor clinical prognosis, are observed in hepatocellular carcinoma (HCC), breast cancer, colon cancer, pancreatic cancer, prostate cancer, and neuroastrocytoma [8, 14–17].